Irit Hemed, MD
Internal Medicine · Fort Myers, FLNPI 1255398665
Payments from drug & device makers
Across 356 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$897
- Lilly USA, LLC$523
- Pfizer$522
- Amgen$404
- Novo Nordisk$356
- Merck$338
- plus $3K from 27 others
What the payments were for
- Food & beverage$5,785100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $897 |
| Lilly USA, LLC | 34 | $523 |
| Pfizer | 38 | $522 |
| Amgen(2 entities) | 27 | $404 |
| Novo Nordisk | 21 | $356 |
| Merck | 19 | $338 |
| AbbVie(2 entities) | 19 | $330 |
| Novartis | 15 | $303 |
| Johnson & Johnson | 20 | $278 |
| Amarin Pharma, Inc. | 14 | $230 |
| Sumitomo Pharma America, Inc. | 9 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $193 |
| Teva Pharmaceuticals USA, Inc. | 10 | $142 |
| Esperion Therapeutics, Inc. | 8 | $137 |
| GSK | 8 | $126 |
| Sunovion Pharmaceuticals Inc. | 6 | $95 |
| Boehringer Ingelheim | 6 | $90 |
| Astellas Pharma US Inc | 6 | $90 |
| Idorsia Pharmaceuticals US Inc | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Exact Sciences | 2 | $50 |
| Corcept Therapeutics | 2 | $46 |
| Braemar Manufacturing, LLC | 1 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Medicure Pharma Inc. | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $23 |
| IBSA Pharma Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
How this compares
$5,785 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 137 | $161,907 |
| JardianceEmpagliflozin | 105 | $138,602 |
| FarxigaDapagliflozin Propanediol | 128 | $117,501 |
| EliquisApixaban | 78 | $110,901 |
| OzempicSemaglutide | 71 | $89,217 |
| RybelsusSemaglutide | 41 | $44,219 |
| XareltoRivaroxaban | 37 | $36,451 |
| JanuviaSitagliptin Phosphate | 19 | $30,556 |
| GemtesaVibegron | 28 | $25,093 |
| MyrbetriqMirabegron | 23 | $21,335 |
| Repatha SureclickEvolocumab | 19 | $19,902 |
| VascepaIcosapent Ethyl | 23 | $18,886 |
| Rosuvastatin Calcium | 877 | $11,637 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $11,251 |
| SynthroidLevothyroxine Sodium | 137 | $11,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $523 | $161,907137 claims |
| Boehringer IngelheimJardiance | $90 | $138,602105 claims |
| Novo NordiskOzempic, Rybelsus | $356 | $133,436112 claims |
| AstraZenecaFarxiga | $897 | $117,501128 claims |
| PfizerEliquis | $522 | $110,90178 claims |
| Johnson & JohnsonXarelto | $278 | $36,45137 claims |
| MerckJanuvia | $338 | $30,55619 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $219 | $25,09328 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $21,33523 claims |
| GSKBreo Ellipta | $126 | $11,25116 claims |
| AbbVieSynthroid | $330 | $11,079137 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $39 | $10,32412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Fort Myers
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.